Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market

Executive Summary

AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.


Related Content

AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer
How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
AstraZeneca Scores Lung Cancer Touchdown, While Clovis Fumbles
How Clovis’ Rociletinib And AstraZeneca’s AZD9291 Development Programs Stack Up
Boehringer Launches Gilotrif At $5,500/Month, Just Under Entrenched Tarceva
DxS Hopes AstraZeneca's Iressa EU Launch Will Help Build Companion Test Business
AstraZeneca's Iressa Use Narrowed: No New Commercial Patients


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts